EP Patent

EP1996266A2 — Nasal delivery

Assigned to Optinose AS · Expires 2008-12-03 · 17y expired

What this patent protects

A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit (20, 24) including a nosepiece (17) for fitting to a nostril of a subject and a nozzle (45) through which substance is in use delivered,…

USPTO Abstract

A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit (20, 24) including a nosepiece (17) for fitting to a nostril of a subject and a nozzle (45) through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasai cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal' cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasa valve, and expand the same in the sagittal plane; and a delivery unit (43, 49, 51) for delivering substance through the nozzle of the nosepiece.

Drugs covered by this patent

Patent Metadata

Patent number
EP1996266A2
Jurisdiction
EP
Classification
Expires
2008-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Optinose AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.